Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

MLA

Craig T. Jordan, et al. “Venetoclax and Azacitidine Followed by Allogeneic Transplant Results in Excellent Outcomes and May Improve Outcomes versus Maintenance Therapy among Newly Diagnosed AML Patients Older than 60.” Bone Marrow Transplantation, vol. 57, Oct. 2021, pp. 160–66. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fa00eb1cb87a3065ff79544495fc67ac&authtype=sso&custid=ns315887.

APA

Craig T. Jordan, Diana Abbott, Daniel A. Pollyea, Jonathan A. Gutman, Marc Schwartz, Clayton A. Smith, Rachel Rabinovitch, Christine McMahon, & Amanda Winters. (2021). Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplantation, 57, 160–166.

Chicago

Craig T. Jordan, Diana Abbott, Daniel A. Pollyea, Jonathan A. Gutman, Marc Schwartz, Clayton A. Smith, Rachel Rabinovitch, Christine McMahon, and Amanda Winters. 2021. “Venetoclax and Azacitidine Followed by Allogeneic Transplant Results in Excellent Outcomes and May Improve Outcomes versus Maintenance Therapy among Newly Diagnosed AML Patients Older than 60.” Bone Marrow Transplantation 57 (October): 160–66. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fa00eb1cb87a3065ff79544495fc67ac&authtype=sso&custid=ns315887.